EP Edge Journal Watch

Niraj Sharma MD FACC FHRS
  • 0,0 (0)
  • CIENCIAS DE LA VIDA

Welcome to EP Edge Journal Watch — where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this bi-weekly podcast distills high-impact cardiovascular and EP research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal — not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

  1. EP Edge Journal Watch #14 (March 2026): AF Ablation at the Extremes: Octogenarians, HFrEF PVI-Only, LAAC, PFA Hemolysis/AKI & Redo Timing

    HACE 5 D

    EP Edge Journal Watch #14 (March 2026): AF Ablation at the Extremes: Octogenarians, HFrEF PVI-Only, LAAC, PFA Hemolysis/AKI & Redo Timing

    In EP Edge Journal Watch Issue 14 (March 2026), Dr. Niraj Sharma breaks down the most clinically “edge-case” decisions in contemporary electrophysiology—where ablation strategy, stroke prevention, and safety monitoring collide. This episode covers: AF ablation in octogenarians (REHEALTH AF): why the signal may be less about short-term hard outcomes and more about symptoms, function, and patient-centered endpoints.Heart failure + AF (POLAR-HF): the case for a standardized PVI-only approach in HFrEF—and when simplicity is the point.LAAC after ablation (OPTION subanalysis): whether left atrial appendage closure changes AF recurrence (and why rhythm success ≠ stroke immunity).Severe spontaneous echo contrast before LAAC (OCEAN-LAAC): when “smoke” is a high-risk biology phenotype that should change surveillance and post-device antithrombotic strategy.Multimorbidity and PVI: what long-term recurrence really looks like in high comorbidity-burden patients—and how to reset goals toward AF burden and symptoms.Pulsed field ablation safety: hemolysis markers (haptoglobin depletion), AKI risk under routine hydration, and who needs tighter post-procedure monitoring (Farapulse vs PulseSelect).Redo ablation timing: evidence that earlier repeat ablation after recurrence may improve rhythm and quality-of-life outcomes.Plus: PACED score for LVEF recovery after AF ablation, LBBAP upgrades for pacing-induced cardiomyopathy, and a cardiology bonus trial (APERITIF) on LV thrombus prevention after anterior STEMI.References and visuals are available with the newsletter on LinkedIn and on Substack (epedge.substack.com).

    33 min
  2. EP Edge Journal Watch Issue 13 (March 2026): Ultrashort AF, ILR Accuracy, Semaglutide + Ablation, PADIT, PCOS, LBBAP and Next-Gen nanosecond PFA (SCENA-AF)

    2 MAR

    EP Edge Journal Watch Issue 13 (March 2026): Ultrashort AF, ILR Accuracy, Semaglutide + Ablation, PADIT, PCOS, LBBAP and Next-Gen nanosecond PFA (SCENA-AF)

    EP Edge Journal Watch — Issue 13 (March 2026) explores a core 2026 EP problem: signal detection (wearables, patches, ILRs) and energy delivery (next-gen PFA) are advancing faster than the clinical rules we use to interpret risk and outcomes.  In this episode, Dr. Niraj Sharma breaks down what’s clinically actionable, what’s methodologically fragile, and what should change practice now versus what needs better evidence. Topics covered (high-level): Ultrashort atrial arrhythmias (30 seconds) and what they may imply on continuous monitoringImplantable loop recorder (ILR) “AF alerts” and why vendor performance is not interchangeable Semaglutide (GLP-1) and AF ablation in obesity: metabolic modulation as an EP strategy, not an afterthoughtNanosecond pulsed field ablation (nsPFA) for paroxysmal AF (SCENA-AF) and what it means for workflow (including anesthesia strategy) A high-stakes coronary spasm signal in a population-enriched cohortLBBAP perforation detection: interpreting iEGMs as phenotype, not just amplitude PADIT score validation by infection subtype—toward phenotype-aware preventionPCOS and long-term arrhythmia risk: a women’s cardiovascular EP domain hiding in plain sight Read the full newsletter (graphics + references): epedge.substack.com Subscribe on LinkedIn (EP Edge Journal Watch): https://lnkd.in/e-Wa4diC Subscribe to EP Edge (Monthly Deep Dives): https://lnkd.in/ep3NdZUz Subscribe Substack: epedge.substack.com

    24 min
  3. EP Edge™ Journal Watch: February 2026 Issue 12: AF Ablation “Success” Reframed: ADVENT-LTO 4-Year PFA Durability, 20-Year PVI Outcomes, Monitoring Rules, CIED Risks & PICM

    23 FEB

    EP Edge™ Journal Watch: February 2026 Issue 12: AF Ablation “Success” Reframed: ADVENT-LTO 4-Year PFA Durability, 20-Year PVI Outcomes, Monitoring Rules, CIED Risks & PICM

    In this episode of EP Edge™ Journal Watch (Issue 12, February 2026), Dr. Niraj Sharma breaks down a deceptively simple question in atrial fibrillation (AF) ablation: what does “success” actually mean—at 1 year, 4 years, and 20 years? We start with ADVENT-LTO, the long-term extension of the randomized ADVENT trial, examining 4-year outcomes of pulse field ablation (PFA) vs thermal ablation—and why redo ablation and hospital-based interventions may matter more than a single headline p-value. Next, we zoom way out with a 20-year pulmonary vein isolation (PVI) cohort, showing how AF behaves like a progressive atrial cardiomyopathy over decades—and why very late recurrences may occur even when PV isolation remains durable. Then we tackle the “quiet drivers” of trial results: monitoring intensity, the 30-second recurrence rule, blanking periods, and AF burden—the design choices that can make technologies look better (or worse) without changing biology. Finally, two practical, real-world segments: ablation in patients with pacemakers/ICDs (MAUDE signal patterns, including resets and generator issues) and pacing-induced cardiomyopathy (PICM) in the leadless era (leadless vs transvenous RV pacing). Full written issue (with references) is on Substack: epedge.substack.com and on LinkedIn Newsletter EP Edge Journal Watch

    25 min
  4. EP Edge™ Journal Watch (Special Edition): Feb 2026 HRS/EHRA Pulsed Field Ablation (PFA) Scientific Statement — Vote Counts, Safety Signals, and Real-World Workflow

    19 FEB

    EP Edge™ Journal Watch (Special Edition): Feb 2026 HRS/EHRA Pulsed Field Ablation (PFA) Scientific Statement — Vote Counts, Safety Signals, and Real-World Workflow

    In this EP Edge™ Journal Watch Special Edition, we unpack the newly released 2026 HRS/EHRA Scientific Statement on Pulsed Field Ablation (PFA) and translate “consensus language” into practical, lab-ready decision-making. This isn’t a surface summary—it’s a critical appraisal of how the statement was built (including the 11-voter model), where the field is truly aligned, and where recommendations may outpace either the evidence base or global clinical reality.  final pfa statement You’ll hear a Consensus Map that separates high-agreement anchors (e.g., access, anticoagulation, sheath discipline) from moderate-consensus workflow preferences (e.g., anesthesia models, ICE use, waiting periods), and the genuinely controversial areas. Then we go deep on what matters most to operators and patients: platform-aware safety and post-market signal management, hemolysis/AKI mitigation tied to lesion burden, phrenic/airway realities, esophageal considerations when lesion sets expand, CIED interaction risk, and why “PFA is a system, not a single technology” should change how you read every recommendation.  final pfa statement Show notes: All graphics and full references are available on epedge.substack.com and on LinkedIn in the EP Edge™ Journal Watch newsletter (Issue 12 Special Edition). Questions/suggestions: email: epedgecast@gmail.com

    17 min
  5. EP Edge Journal Watch Issue 11 February 2026: Varipulse Safety Signal, ElectroPulse PFA, Farapoint CTI Ablation, Leadless Pacemaker Infection & EP Occupational Hazards

    16 FEB

    EP Edge Journal Watch Issue 11 February 2026: Varipulse Safety Signal, ElectroPulse PFA, Farapoint CTI Ablation, Leadless Pacemaker Infection & EP Occupational Hazards

    In this episode of EP Edge Journal Watch, we review several developments that directly impact modern electrophysiology practice — from pulsed field ablation safety to operator health. We begin with the real-world Varipulse experience, where early neurovascular events dropped dramatically after workflow modification and reduction of lesion stacking, highlighting that PFA success depends as much on procedural execution as on device design. We then discuss the first-in-human ElectroPulse mapping-ablation platform and what its early durability signals suggest about integrated catheter systems and standardized ablation protocols.  We next turn to right-sided ablation safety. The episode examines cavotricuspid isthmus pulsed field ablation, the mechanism of coronary vasospasm, and the high-dose nitroglycerin protection strategy used in studies. We also review emerging intracoronary imaging findings suggesting possible delayed coronary arterial remodeling after PFA. Device and structural therapy updates follow, including Amulet 360 left atrial appendage occlusion sealing performance and long-term outcomes of a small-diameter ICD lead platform designed to improve lead durability.  Finally, we discuss practical EP laboratory implications: a simplified pacing maneuver to distinguish AV nodal from septal accessory pathway conduction, the first reported infection involving an atrial leadless pacemaker, and new data on occupational hazards in electrophysiology — including radiation exposure, cataracts, orthopedic injury, and pregnancy-related workforce considerations. The central message is clear: electrophysiology outcomes increasingly depend on workflow discipline, protection strategies, and operator sustainability.  Full references, figures, and detailed graphics are available in the LinkedIn Newsletter: EP Edge Journal Watch — Issue 11 (February 2026) and on Substack at epedge.substack.com. Questions or feedback: epedgecast@gmail.com.

    13 min
  6. EP Edge Journal Watch Issue 10, February 2026: Pulsed Field Ablation Durability, AF Ablation Outcomes, Wearable AF Detection, ICD and VT Insights

    9 FEB

    EP Edge Journal Watch Issue 10, February 2026: Pulsed Field Ablation Durability, AF Ablation Outcomes, Wearable AF Detection, ICD and VT Insights

    EP Edge Journal Watch: Feb 2026 Issue 10 In this episode of EP Edge Journal Watch, we examine the latest developments shaping the future of cardiac electrophysiology, with a focus on pulsed field ablation durability, atrial fibrillation ablation outcomes, wearable AF detection, ventricular tachycardia ablation endpoints, autonomic modulation, and ICD patient outcomes. Pulsed field ablation has rapidly transformed AF ablation due to its safety and efficiency, but long-term success depends on durable pulmonary vein isolation. We explore how next-generation catheter architecture, electrode geometry, and tissue contact optimization are redefining durability and advancing the effectiveness of catheter ablation for atrial fibrillation. This episode also highlights the expanding understanding that atrial fibrillation is driven not only by electrical triggers but also by systemic metabolic and autonomic factors. We discuss how metabolic therapies, including GLP-1 receptor agonists, may improve long-term rhythm control after ablation by modifying atrial substrate and inflammation. In parallel, wearable technologies such as smartwatches are accelerating AF detection, enabling earlier diagnosis of asymptomatic atrial fibrillation and fundamentally changing screening, referral, and management pathways for electrophysiologists and cardiologists. Beyond atrial fibrillation, we explore emerging advances in cardioneuroablation as a precision therapy for functional bradycardia and reflex syncope, the profound clinical impact of mental health disorders on outcomes following ICD implantation, and the ongoing challenges in defining meaningful success metrics in ventricular tachycardia ablation. We also examine the growing importance of sustainability, safety, and regulatory oversight in electrophysiology practice, including the evolving role of catheter reprocessing. Together, these topics reflect a broader transformation in electrophysiology toward an integrated approach that addresses arrhythmia mechanisms, substrate biology, patient physiology, and long-term clinical outcomes. Full references, detailed discussion, graphs, and visual summaries for this episode are available on the EP Edge Journal Watch newsletter on LinkedIn, as well as the full long-form edition now available on Substack at epedge.substack.com. If you have questions, suggestions, or feedback, please email epedgecast@gmail.com.

    26 min
  7. EP Edge Journal Watch Special Edition: VOLT IDE One-Year Results in Context: ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-Per-AF & U.S. PFA Pivotal Trials

    6 FEB

    EP Edge Journal Watch Special Edition: VOLT IDE One-Year Results in Context: ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-Per-AF & U.S. PFA Pivotal Trials

    Pulsed field ablation (PFA) has rapidly reshaped atrial fibrillation ablation, but true clinical validation depends on durable one-year outcomes, not early feasibility or acute safety alone. In this EP Edge Journal Watch Special Edition, Dr. Niraj Sharma delivers a comprehensive, system-level analysis of the Abbott VOLT IDE one-year data, now completing the 12-month efficacy and safety landscape across major U.S. PFA platforms. This episode critically reviews and contextualizes results from the VOLT IDE trial alongside other pivotal and near-pivotal studies, including ADVENT, ADVANTAGE-AF, AdmIRE, SPHERE-9 first-in-human, and SPHERE-Per-AF. The discussion spans paroxysmal, persistent, and advanced AF populations, with attention to how ablation strategy (PVI-only vs adjunctive lesions), patient risk profile, and post-ablation monitoring intensity influence reported outcomes. Key themes include one-year efficacy versus composite effectiveness, freedom from atrial arrhythmias, repeat procedures, and major safety endpoints such as stroke, tamponade, and esophageal injury. Rather than ranking technologies, this episode emphasizes methodology, trial design, and clinical context, explaining why efficacy signals differ across studies and how these data should be interpreted in everyday electrophysiology practice. For additional references, detailed tables, graphics, and deeper comparative analysis, visit the LinkedIn EP Edge newsletter and Substack at ephedge.substack.com. If you have suggestions or concerns, you can reach Dr. Sharma at ephedgecast@gmail.com

    9 min
  8. EP Edge Journal Watch — Issue 9 Redefining Ventricular Tachycardia Care: From Noninvasive Radioablation to Leadless, Modular, and Drug-Based Strategies

    2 FEB

    EP Edge Journal Watch — Issue 9 Redefining Ventricular Tachycardia Care: From Noninvasive Radioablation to Leadless, Modular, and Drug-Based Strategies

    In EP Edge Journal Watch – Issue 9 (February 2026), we take a comprehensive, clinically grounded look at the evolving management of ventricular tachycardia (VT)—from last-line noninvasive therapies to next-generation devices, pharmacologic strategy, and infection prevention. This episode critically reviews the STRA-MI-VT trial, examining stereotactic arrhythmia radioablation (STAR) for refractory VT with a unique focus on coronary safety using serial coronary CT angiography. We explore why early VT suppression occurs after radioablation and what emerging mechanistic data suggest about electrophysiologic remodeling beyond fibrosis. We then turn to contemporary VT decision-making with a deep dive into the VANISH2 substudy, comparing first-line catheter ablation with antiarrhythmic drug therapy, highlighting where ablation clearly outperforms sotalol and rivals amiodarone—without long-term extracardiac toxicity. Next, we examine modular defibrillation systems combining subcutaneous ICDs with leadless antitachycardia pacing, unpacking ATP effectiveness, complication rates, and the critical nuance behind so-called “inappropriate” therapies. We also review the latest data on dual-chamber leadless pacing, demonstrating high real-world AV synchrony and outlining what questions remain unanswered. The episode concludes with two essential but often under-discussed domains: Why antiarrhythmic drugs still matter in 2026, using updated EHRA frameworks for safer, more rational useWhat the CHLOVIS trial teaches us about CIED infection prevention—and why skin antisepsis alone is not the decisive factorAs always, EP Edge Journal Watch prioritizes clinical context, trial design, limitations, and practical implications, helping electrophysiologists cut through signal versus noise.  Looking for More Detail? For expanded references, trial tables, figures, and visual summaries, visit the EP Edge Journal Watch LinkedIn Newsletter. Each study discussed in this episode is accompanied there by: Trial-at-a-glance summariesKey graphs and imaging highlightsStructured critical appraisalClinical interpretation beyond the abstractIf you prefer to read, review figures, or reference the data later, the LinkedIn newsletter is the ideal companion to this podcast episode. If you have questions, feedback, or clinical thoughts, feel free to reach out directly at epedgecast@gmail.com

    13 min
Ver todo (17)

Información

Welcome to EP Edge Journal Watch — where cardiac electrophysiology meets evidence, precision, and perspective. Hosted by Dr. Niraj Sharma, this bi-weekly podcast distills high-impact cardiovascular and EP research into clear, clinically meaningful insights. Each episode goes beyond headlines and abstracts to uncover what new studies actually mean for patient care, decision-making, and the future of electrophysiology. What EP Edge Journal Watch stands for: Evidence-based practice Precision electrophysiology A forward-thinking, edge-driven approach to how we interpret and apply data in real-world clinical settings. Whether you’re an electrophysiologist, cardiologist, researcher, trainee, or allied health professional, EP Edge Journal Watch brings you the signal — not the noise. Expect sharp summaries, thoughtful commentary, and practical takeaways designed for the busy clinician who wants to stay ahead of the curve

Ficha técnica

  • Creado por
    Niraj Sharma MD FACC FHRS
  • Años en activo
    2025 - 2026
  • Episodios
    17
  • Clasificación
    Apto
  • Derechos de autor
    © 2026 Niraj Sharma MD FACC FHRS
  • Proveedor

Quizá también te guste